Schwarz Pharma Articles
US FDA approves Pfizer's Toviaz
10 November 2008
Mylan's generic Parcopa gets FDA OK
29 September 2008
Vimpat gets nod for epilepsy from CHMP
7 July 2008
Stock Commentary - Europe - week to March 3, 2008
10 March 2008
UCB's 2007 net profit down 59% on M&A
10 March 2008
UCB opens Irish production plant
15 October 2007
UCB's 1st-half profits fall 39% on Schwarz buy
6 August 2007
Schwarz' 1st-half net profit falls 30%
6 August 2007
USB appoints Detlef Thielgen as CFO
23 July 2007
Neupro patch for PD patients in the USA
23 July 2007
US FDA approves Schwarz' Neupro
14 May 2007
Schwarz' sales drop 6.2% in 1st qtr of 2007
7 May 2007
Cimzia key drug in UCB 2007 R&D update
7 May 2007
Newron appoints Carlos De Sousa CBO
7 May 2007
Neupro patch launched in UK for all stages of PD
29 January 2007
Pierre Fabre buys UCB's European OTC business
15 January 2007
Schwarz Pharma's rotigotine performs well in PD trial
8 January 2007
4SC takes on full rights to urology project
18 December 2006
Stock Commentary - Europe - week to Dec 11, 2006
18 December 2006
Schwarz' lacosamid cuts seizures 14.4%
11 December 2006
UCB publishes offer document for Schwarz Pharma
20 November 2006
Schwarz back on track
6 November 2006
Stock Commentary - Europe - week to Sept 25, 2006
2 October 2006
Pfizer saves Schwarz from dip into the red
31 July 2006
Schwarz's 1st-qtr sales up 4% to 274M euros
8 May 2006
Stock Commentary - Europe - week to April 17, 2006
24 April 2006
Schwarz' Neupro launched in the UK
10 April 2006
Schwarz' Neupro launched in the UK
10 April 2006
Schwarz Pharma's revenue up 4.6% in 2005
27 February 2006
Schwartz Pharma boosted by US sales
9 May 2005
Stock Commentary - Europe
18 April 2005
Schwarz Pharma beats forecasts but sales and profits down
28 February 2005
Schwarz Pharma wins Univasc case
17 January 2005
Schwarz halts trials of Ranbaxy's RBX 2258
15 November 2004
Schwarz' sales drop 17% for 3rd-qtr 2004
1 November 2004
Schwarz Pharma Japan appointment
27 September 2004
FDA approves Schwarz Pharma's Parcopa
13 September 2004
Schwarz' 1st-half 2004 sales tumble 49.9%
2 August 2004
Ranbaxy UK in generic drugs price row
5 July 2004
Mylan settles for $37.5M from Schwarz
5 July 2004
Schwarz Pharma's sales dive 51.7%
10 May 2004
Merck KGaA's organic pharma sales up 4.3%
3 May 2004
Schwarz wins US Losec generics battle
22 December 2003
Schwarz hit by more omeprazole generics
3 November 2003
Sales near flat at Merck KGaA in third qtr, generics grow as pipeline is restructured
3 November 2003
Merck KGaA reports strong third quarter
3 November 2003
German drug industry investment stays high despite reform
29 September 2003
Schwarz still riding high on generic Prilosec
4 August 2003
Teva's generic Univasc cleared in USA
19 May 2003
India's Ranbaxy sees Q1 profits soar 78%
12 May 2003
Schwarz makes progress with epilepsy drug
14 April 2003
Schwarz lifts forecasts on strong generic sales
14 April 2003
Able Lab's generic methocarbamol cleared by FDA
24 March 2003
Schwarz forecasts two-fold earnings growth in 2003
3 March 2003
AstraZeneca shares hit three-month low
20 January 2003
Blansett and Schwarz Pharma team up for ProctoFoam HC
5 August 2002
Nascobal use extended, but Schwarz deal ended
8 July 2002
Drugmakers warn over German generics move
17 June 2002
Schwarz exceeds profit expectations
20 May 2002
Nasal vitamin B12 drug cleared in Sweden
28 January 2002
Schwarz Pharma looks to have turned corner
12 November 2001
CORRECTION: CEPA's valsartan
8 August 2001
CORRECTION: Novartis/Schwarz deal
7 August 2001
Novartis and Schwarz extend valsartan deal
23 July 2001
Axcan reimburses loan to Schwarz Pharma
2 July 2001
Schwarz sells back hormone rights
8 June 2001
Axcan financing raises C$51 million
1 June 2001
Profits slide at Schwarz Pharma
15 May 2001
Schwarz gets generic Prilosec OK in USA
10 May 2001
CeNes turnover leaps to L6.6 million
5 April 2001
Schwarz Pharma net income up 65% as operating loss narrows
21 February 2001
Bioglan Pharma to buy Pharmacia morphine products
14 February 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
Positive Ph II for CeNeS morphine variant
30 January 2001
Schwarz Pharma loses R&D head to Elan
5 December 2000
Schwarz Pharma to sell generics business
29 November 2000
CeNeS' Moraxen cleared in UK for cancer pain
5 July 2000
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
